Related Experiment Video
Updated: Oct 11, 2025

12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
15.0K
Blinatumomab Nonresponse Is Associated with Poor CD19-CAR Outcome in B-ALL
Cancer Discovery
|December 4, 2021
Abstract:
Blinatumomab nonresponders have worse CD19-CAR response than responders or blinatumomab-naïve patients.

